BSX
$86.95
Boston Scientific
$.18
.21%
BSX
Earnings Whisper ®
$0.61
3rd Quarter September 2024
Consensus:  $0.58
Revenue:  $4.03 Bil
Wednesday
Oct 23
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BSX reports earnings?
Beat
Meet
Miss

Where is BSX's stock price going from here?
Up
Flat
Down
Stock chart of BSX
Analysts
Summary of analysts' recommendations for BSX
Score
Grade
Pivots
Resistance
$89.32
$88.71
$87.74

$87.12

Support
$86.15
$85.54
$84.57
Tweet
Growth
Description
Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
Peers
StrykerAbbottBecton, DickinsonWaters3MBaxter InternationalTeleflexResMedIntegra LifeSciences HoldingsMerit Medical Systems